<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386552</url>
  </required_header>
  <id_info>
    <org_study_id>ISI-2015-1</org_study_id>
    <nct_id>NCT03386552</nct_id>
  </id_info>
  <brief_title>A Study of Lidocaine Pertubation as a Treatment for Unexplained Infertility</brief_title>
  <official_title>A Randomized, Double Blind, Controlled, Parallel Groups, Multi-center Phase II Clinical Study of Lidocaine Pertubation as a Treatment for Couples With Unexplained Infertility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isifer AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vinnova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Isifer AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present investigation is evaluating a method for improving pregnancy outcome of couples&#xD;
      with unexplained infertility. The method utilizes an adjuvant pre-treatment prior to&#xD;
      insemination, that is pertubation, i.e. flushing the uterus and fallopian tubes before&#xD;
      insemination with a specially developed solution with the aim to increase fertility. The&#xD;
      clinical trial is a phase II double blind, randomized, controlled and multi-center trial .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Couples interested in participating in the clinical study must have undergone a complete&#xD;
      investigation for their infertility and have at least one year of unsuccessful attempts to&#xD;
      achieve pregnancy. Following inclusion in the study, patients will be monitored with vaginal&#xD;
      ultrasound to ensure a leading follicle of at least 18 mm.The subjects with one or two&#xD;
      follicles ≥18 mm will be given Ovitrelle® (Merck), dose 250 ug (6500 IU) of Human Chorionic&#xD;
      Gonadotropin (HCG), subcutaneously for ovulation induction. 12-24 h after the HCG injection,&#xD;
      patients will be randomized and pertubated with either test or control solution.&#xD;
&#xD;
      12 -24 hours after the pertubation insemination (IUI) will be given to all patients. A blood&#xD;
      sample is taken 14-17 days after IUI, for analysis of serum HCG level and possible pregnancy.&#xD;
      In case of positive answer a second confirmatory sample will be obtained 48-72 hours later.&#xD;
      In case of confirmed elevated HCG, the clinical pregnancy (CP) will be assessed with vaginal&#xD;
      ultrasound examination 6-7 week after IUI. Baby take home rate data will be collected for&#xD;
      couples with clinical pregnancy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>day 14-17 after IUI</time_frame>
    <description>serum-HCG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baby take home rate</measure>
    <time_frame>At delivery / Miscarriage</time_frame>
    <description>Delivery of baby</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Unexplained Infertility</condition>
  <arm_group>
    <arm_group_label>Isifera+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are pertubated with Isifer+ solution containing lidocaine 0.5 mg/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buffer</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects are pertubated with a buffer solution without lidocaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isifera+</intervention_name>
    <description>Pertubation solution of lidocaine 0.5 mg ml in Ringer-Acetate buffer</description>
    <arm_group_label>Isifera+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buffer</intervention_name>
    <description>Pertubation solution of Ringer-Acetate buffer</description>
    <arm_group_label>Buffer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Females with, unexplained infertility, 20-38 years of age. Normal menstrual cycle length of&#xD;
        26-35 days, male partner 20-70 years of age, Duration of infertility should have lasted&#xD;
        more than one year and subject should have signed informed consent.&#xD;
&#xD;
        Couples must fulfil all laboratory tests for inclusion, negative HIV-1, HCV, HBV, CMV&#xD;
        virology, chlamydia and syphilis. For female also negative toxoplasmosis, rubella and&#xD;
        hormonal screen within normal range. Furthermore patent fallopian tubes should be confirmed&#xD;
        by ultrasound hysterosalpingography and males should present a normal semen analysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Continuous treatment with NSAID, corticosteroids or other drugs, which can cause an&#xD;
        increased risk of infection, clinical signs of PID, known hypersensitivity to local&#xD;
        anaesthetics, non-patent fallopian tubes, abnormal uterine cavity, submucous myoma &gt; 2 cm&#xD;
        in diameter, any disease or laboratory finding considered of importance by the investigator&#xD;
        not to include the patient, laparoscopically confirmed endometriosis of greater severity&#xD;
        than mild, endometriosis of any severity with adhesions. More than 2 previous inseminations&#xD;
        or previous unsuccessful IVF treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack Spira, Md PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Isifer AB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tomasz Rokicki, MD, PhD</last_name>
    <phone>+48 500 900 888</phone>
    <email>t-rokicki@invimed.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>InviMed-T sp. z o.o</name>
      <address>
        <city>Warszawa</city>
        <zip>02-532</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Rokicki, MD, PhD</last_name>
      <phone>+48 500 900 888</phone>
      <email>t-rokicki@invimed.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/18281242</url>
    <description>A new rapid and effective method for treatment of unexplained infertility.</description>
  </link>
  <results_reference>
    <citation>Edelstam G, Sjösten A, Bjuresten K, Ek I, Wånggren K, Spira J. A new rapid and effective method for treatment of unexplained infertility. Hum Reprod. 2008 Apr;23(4):852-6. doi: 10.1093/humrep/den003. Epub 2008 Feb 15.</citation>
    <PMID>18281242</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

